Table 1.
Group I | Sham wounds (untreated control) |
Group II | Treated with VEGF-s–e-hADMSCs |
Group III | Treated with HIF-1α–s–e-hADMSCs |
Group IV | Treated with s–n-hADMSCs |
Group V | Treated with rADMSCs and VEGF-s–e-hADMSCs |
Group VI | Treated with rADMSCs and HIF-1α–s–e-hADMSCs |
Group VII | Treated with rADMSCs |
VEGF over expressed secretome of engineered hADMSCs (VEGF-s–e-hADMSC); HIF-1α over expressed secretome of engineered hADMSCs (HIF-1α–s–e-hADMSCs); Secretome of non-engineered hADMSCs (s–n-hADMSCs); Rabbit ADMSCs (rADMSCs)